스카이 바이오사이언스SKYE 주가

♻️ 재탕[8-K] 중대 사건 — 8-K

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

No Serious Adverse Events or Adverse Events of Special Interest Were Reported Following 4 Weeks of TreatmentSAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that the Cohort Review Committee (CRC) responsible for reviewing safety data generated from the CBeyond Part C Expansion Study, and for approving the opening o

Skye Bioscience Says Cohort Review Committee Unanimously Approves Opening Second Cohort Of CBeyond Part C Expansion Study

Skye Bioscience, Inc. (NASDAQ:SKYE), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that the Cohort Review Committee

[8-K] 중대 사건 — 8-K

♻️ 재탕UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

CBeyond™ Expansion Study (Part C) initiated; Cohort Review Committee review scheduled for May 18, 2026, to evaluate available safety data and potential progression to Cohort 2 SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the fir

Skye Bioscience : Corporate Presentation View Presentation ( 260511 Skye Corporate Presentation )

May 2O26 Developing Innovative Medicines to Treat Obesity and Other Metabolic Diseases Nasdaq: SKYE ...

♻️ 재탕Skye Bioscience : UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

UPDATE - Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update May 12, 2026 1:33 pm EDT Download as PDF CBeyond™ Expansion Study ...

Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

CBeyond™ Expansion Study (Part C) initiated; Cohort Review Committee review scheduled for May 18, 2026, to evaluate available safety data and potential progression to Cohort 2Engaged Lilly Catalyze360 to provide strategic guidance on nimacimab TPP and Phase 2b trial design SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors

Skye Bioscience Q1 EPS $(0.32) Misses $(0.31) Estimate

Skye Bioscience (NASDAQ:SKYE) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.31) by 3.23 percent. This is a 14.29 percent decrease over losses of $(0.28) per share from

[10-Q] 분기 실적 — 10-Q